Search results for "High-risk"

showing 3 items of 33 documents

The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes

2007

increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…

medicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and MetabolismAtorvastatinPharmacologyEndocrinologyEzetimibeInternal medicineInternal MedicineHumansMedicineGemfibrozilCholesterol absorption inhibitorNational Cholesterol Education ProgramHypolipidemic Agentssmall dense LDL subclasses fibrates statins ezetimibe diabetes high-riskFenofibrateBezafibratebusiness.industryHypertriglyceridemiaGeneral Medicinemedicine.diseaseLipoproteins LDLMolecular WeightEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)businessmedicine.drugExperimental and Clinical Endocrinology & Diabetes
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Lipīdu profila raksturojums un to atbilstība vadlīniju mērķiem koronārās sirds slimības pacientiem, kas stacionēti Latvijas Kardioloģijas centrā

2018

Ievads: Kardiovaskulārās slimības (KVS) mirstības ziņā joprojām ieņem pirmo vietu pasaulē. Latvijā 2014. gadā tās veidoja 64% no visiem nāves cēloņiem sievietēm un 49% no visiem nāves cēloņiem vīriešiem (OECD, 2017). Jo īpaši, zema blīvuma lipoproteīnu holesterīns (ZBLH) ir galvenais terapeitiskais mērķis, aizkavējot saslimšanu ar KVS. Nesen papildinātās dislipidēmijas ārstēšanas vadlīnijas nosaka ļoti augsta riska pacientiem ZBLH mērķa līmeni <1,8 mmol/L un sākotnējā ZBLH līmeņa pazemināšanu vismaz par 50%. Mērķis: Analizēt lipīdu mērķa līmeņu sasniegšanas biežumu – ZBLH <1,8 mmol/L un ne - ABLH <2,6 mmol/L, un analizēt lipīdus pazeminošo līdzekļu (LPL) lietošanu starp pacientiem ar ļoti a…

very high-risk patientsCHDstatin therapyECS/EAS guidelinesLDL-CMedicīna
researchProduct